Method of detecting cancer by measuring lipid-peroxidation using NMR

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a blood component sample from a patient to be tested to proton nuclear magnetic resonance spectroscopy to generate a NMR spectrum from which undesirable signals have been suppressed;
• b) selecting a lipoprotein resonance line for lipid peaks in said spectrum;
• c) measuring the full width at half height of said resonance line;
• d) classifying the full width measured into either a category of normal full widths or into a category of abnormal full widths as compared to a predetermined standard for which abnormal full widths indicate the presence of cancer;
• e) for measured full width readings classified as abnormal in step d), measuring the triglyceride level of the blood component sample;
• f) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• g) for component samples having above normal levels of triglycerides, subjecting the blood component sample to a second proton nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• h) selecting a resonance line for lipoproteins in the region in said spectrum;
• i) measuring the intensity of said resonance line;
• and
• j) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a blood component sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum from which undesirable signals have been suppressed;
• b) selecting a plurality of lipoprotein resonance lines from lipid peaks in said spectrum;
• c) measuring the full width at half-height of each of said resonance lines;
• d) deriving from all full widths so measured a composite linewidth;
• e) classifying the composite linewidth derived into a category of normal composite linewidths or into a category of abnormal composite linewidths as compared to a predetermined standard for which abnormal composite linewidths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the blood component sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for blood component samples having above normal levels of triglycerides, subjecting the blood component sample to a second proton nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a plurality of resonance lines for lipoproteins in the region in said spectrum;
• j) measuring the average areas for each of said resonance lines line;
• and
• k) classifying the second proton NMR spectrum into a category of normal or into a category of abnormal as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a blood component sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum from which undesirable signals have been suppressed;
• b) selecting a plurality of lipoprotein resonance lines from lipid peaks in said spectrum;
• c) measuring the full width at half-height of each of said resonance lines;
• d) deriving from all full widths so measured a composite linewidth;
• e) classifying the composite linewidth derived into a category of normal composite linewidths or into a category of abnormal composite linewidths as compared to a predetermined standard for which abnormal composite linewidths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the blood component sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for blood component samples having above normal levels of triglycerides, subjecting the blood component sample to a second proton nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a plurality of resonance lines for lipoproteins in the region in said spectrum;
• j) measuring the intensity for each of said resonance lines;
• and
• k) classifying the second proton NMR spectrum into a category of normal or into a category of abnormal as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• b) selecting an NMR resonance line in said spectrum from a non-water component of said sample;
• c) measuring the full width at half-height of said resonance line;
• d) classifying the full width measured into either a category of normal full widths or into a category of abnormal full widths as compared to a predetermined standard for which abnormal full widths indicate the presence of cancer;
• e) for measured full widths classified as abnormal full widths, measuring the triglyceride levels of the sample;
• f) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• g) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• h) selecting a resonance line for lipoproteins in the region in said spectrum;
• i) measuring the area of said resonance line;
• and
• j) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps

• a) subjecting a sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• b) selecting an NMR resonance line in said spectrum from a non-water component of said sample;
• c) measuring the full width at half-height of said resonance line:
• d) classifying the full width measured into either a category of normal full widths or into a category of abnormal full widths as compared to a predetermined standard for which abnormal full widths indicate the presence of cancer;
• e) for measured full widths classified as abnormal full widths, measuring the triglyceride levels of the sample;
• f) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• g) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• h) selecting a resonance line for lipoproteins in the region in said spectrum;
• i) measuring the intensity of said resonance line;
• and
• j) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• b) selecting a plurality of NMR resonance lines in said spectrum from a non-water component of said sample;
• c) measuring the full width at half-height of each of said lines;
• d) deriving from all full widths so measured a composite linewidth;
• e) classifying the composite linewidth so derived into a category of normal composite linewidths or into a category of abnormal composite linewidths as compared to a predetermined standard for which abnormal composite linewidths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the area of said resonance line;
• and
• k) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a sample from a patient to be tested to nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• b) selecting a plurality of NMR resonance lines in said spectrum from a non-water component of said sample;
• c) measuring the full width at half-height of each of said lines;
• d) deriving from all full widths so measured a composite linewidth;
• e) classifying the composite linewidth so derived into a category of normal composite linewidths or into a category of abnormal composite linewidths as compared to a predetermined standard for which abnormal composite linewidths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the intensity of said resonance line;
• and
• k) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a sample of blood plasma, bone marrow plasma or spinal fluid to proton nuclear magnetic resonance spectroscopy to generate an NMR spectrum from which the water signal has been suppressed;
• b) selecting the resonance lines of the methyl and methylene groups of the lipoprotein lipids in said spectrum;
• c) measuring the full width at half-height of each of said resonance lines;
• d) computing an average width from the full widths so measured;
• e) classifying the average width computed into the category of normal average widths or into the category of abnormal average widths as compared to a predetermined standard for which abnormal average widths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the blood component sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the area of said resonance line;
• and
• k) classifying the NMR spectrum into a category of normal spectrum or into a Category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method of diagnosing the presence of cancer in a living patient, comprising the following steps:

• a) subjecting a sample of blood plasma, bone marrow plasma or spinal fluid to proton nuclear magnetic resonance spectroscopy to generate an NMR spectrum from which the water signal has been suppressed;
• b) selecting the resonance lines of the methyl and methylene groups of the lipoprotein lipids in said spectrum;
• c) measuring the full width at half-height of each of said resonance lines;
• d) computing an average width from the full widths so measured;
• e) classifying the average width computed into the category of normal average widths or into the category of abnormal average widths as compared to a predetermined standard for which abnormal average widths indicate the presence of cancer;
• f) for measured composite linewidths classified as abnormal composite linewidths, measuring the triglyceride levels of the blood component sample;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for samples having above normal levels of triglycerides, subjecting the sample to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the intensity of said resonance line;
• and
• k) classifying the NMR spectrum into a category of normal spectrum or into a category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method for detecting cancer comprising:

• a) establishing a value for at least one NMR parameter for nuclei of at least one moiety associated with a constituent, other than water, of a lipid-containing bodily fluid of cancer-free subjects;
• b) exposing the same type bodily fluid of a subject to be diagnosed for cancer to a magnetic field and radio-frequency energy to generate a nuclear magnetic resonance spectrum;
• c) processing the nuclear magnetic resonance spectrum to obtain a value for said parameter of said moiety nuclei;
• d) comparing the value established for said parameter in (a) with the value obtained in (c);
• e) classifying the value so established into either a category of normal or into a category of abnormal as compared to a predetermined standard for which abnormal value widths indicate the presence of cancer;
• f) for measured value widths classified as abnormal value widths, measuring the triglyceride levels of the bodily fluid;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for bodily fluids samples having above normal levels of triglycerides, subjecting the bodily fluid to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the area said resonance line;
• and
• k) classifying the NMR spectrum into the category of normal spectrum or into the category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.

A method for detecting cancer comprising:

• a) establishing a value for at least one NMR parameter for nuclei of at least one moiety associated with a constituent, other than water, of a lipid-containing bodily fluid of cancer-free subjects;
• b) exposing the same type bodily fluid of a subject to be diagnosed for cancer to a magnetic field and radio-frequency energy to generate a nuclear magnetic resonance spectrum;
• c) processing the nuclear magnetic resonance spectrum to obtain a value for said parameter of said moiety nuclei;
• d) comparing the value established for said parameter in (a) with the value obtained in (c);
• e) classifying the value so established into either a category of normal or into a category of abnormal as compared to a predetermined standard for which abnormal value widths indicate the presence of cancer;
• f) for measured value widths classified as abnormal value widths, measuring the triglyceride levels of the bodily fluid;
• g) classifying the triglyceride level so measured into the category of normal levels or above normal levels;
• h) for bodily fluids samples having above normal levels of triglycerides, subjecting the bodily fluid to a second nuclear magnetic resonance spectroscopy to generate an NMR spectrum;
• i) selecting a resonance line for lipoproteins in the region in said spectrum;
• j) measuring the intensity of said resonance line;
• and
• k) classifying the NMR spectrum into the category of normal spectrum or into the category of abnormal spectrum as compared to a predetermined standard for which abnormal spectrum indicate the presence of cancer.